Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 induction study of duvakitug in moderate to severe active ulcerative colitis
CTR20260389Phase 3Active
- Sponsor
- Sanofi
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing duvakitug with placebo (2 arms). Primary endpoint: Proportion of participants achieving clinical remission according to the modified Mayo score. Started Jun 2026; status: active.
02
Drugs
duvakitug
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20260389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260389.